Characterization and Experimental Use of a Monospecific Antiserum to Factor IX^[*]

Summary

Purified human factor IX was used to develop xenogeneic neutralizing and precipitating antibodies. The final antiserum (R2) neutralized only factor IX and was equivalent to 220 Bethesda-inhibitory units. It showed two precipitating lines, one of which disappeared after absorption with human albumin. On immunodiffusion and Laurell immunoelectrophoresis, the albumin-absorbed R2 antiserum showed one precipitin line of identity, or one rocket respectively, with normal plasma, a Red Cross factor IX preparation (rich in factors IX, II and X), the orginal antigen, and Hemophilia-B antigen-positive plasmas. No line or rocket developed with normal plasma absorbed with aluminum hydroxide or with antigen-negative Hemophilia B plasmas. We concluded that after absorption with albumin the antiserum R2 contained only factor IX neutralizing and precipitating antibodies.

Experiments with various factor IX concentrates revealed that the majority contained excess factor IX antigen compared to their coagulant activity. In addition, crossed antigen-antibody electrophoresis uncovered differences in the migration of the factor IX of Konyne preparations, when done in the presence of EDTA or calcium.

This monospecific antiserum to human factor IX was subsequently used to investigate a large population of hemophilia B patients and carriers.

^* Presented at the The VIth International Congress on Thrombosis & Haemostasis, June 26-July 2, 1977, Philadelphia, Pa.

• References

• 1 Chandra S, Pechet L. 1973; The separation of clotting factors II. Purification of human factor IX (PTC) by isoelectric focusing. Biochemica Biophysica Acta 328: 456
• 2 Davis BJ. 1964; Disc electrophoresis II. Method and application to human serum proteins. Annals of the New York Academy of Sciences 121: 404
• 3 Hardisty RM, Macpherson JC. 1962; A one-stage factor VIII (anti-hemophilic globulin) assay and its use on venous and capillary plasma. Thrombosis et Diathesis Haemorrhagica 7: 215
• 4 Kasper C, Aledort LM, Counts RB, Edson JR. et al. 1975; A more uniform measurement of factor VIII inhibitors. Thrombosis et Diathesis Haemorrhagica 32: 869
• 5 Kasper CK, ØSterud B, Minami JY, Shonick W, Rappaport SI. 1977; Hemophilia A: Characterization of genetic variants and detection of carriers. Blood 50: 351
• 6 Laurell CB. 1965; Antigen-antibody crossed electrophoresis. Annals of Biochemistry 10: 358
• 7 Laurell CB. 1966; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Annals of Biochemistry 15: 45
• 8 Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. 1951; Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193: 265
• 9 Matsuoda M, Masakazu J, Takahashi K, Sakuragama N. 1976; An immunologic method for detection of the carrier of hemophilia B. Thromobosis et Diathesis Haemorrhagica 36: 441
• 10 Menache D, Aronson D. 1977; Heterogeneity of factor IX in therapeutic concentrates. Abstract, VI International Congress of Thrombosis and Haemostasis, Philadelphia, Pa Thrombosis and Haemostasis 38: 189
• 11 Meyer D, Fressinaud E, Dreyfus M, Larrieu MJ. 1975. Study of human factor IX variants with an immunoabsorption technique. In: Hemker HD, Veltkamp TT. (Eds.) Prothrombin and related coagulation factors. Leiden University Press; pp 264 273
• 12 Ørstavik KH, Østerud B, Prydz H, Berg K. 1975; Electroimmunoassay of factor IX in hemophilia B. Thrombosis Research 7: 373
• 13 Østerud B, Flengsrud R. 1975; Purification and some characteristics of the coagulation factor IX from human plasma. Biochemistry Journal 145: 469
• 14 Pechet L, Smith JA. 1970; The separation of clotting factors II (prothrombin) and IX (plasma thromboplastin component) by isoelectric focusing. Biochemica Biophysica Acta 200: 475
• 15 Pechet L, Tiarks CY, Stevens J, Sudhindra R, Lipworth L. 1977; Relationship of factor IX antigen and coagulant in hemophilia B patients and carriers. Thrombosis and Haemostasis 40
• 16 Ratnoff OD, JONES PK. 1977; The laboratory diagnosis of the carrier state for classic hemophilia. Annals of Internal Medicine 86: 521
• 17 Rosenberg JS, Mckenna PW, Rosenberg RD. 1975; Inhibition of human factor IXa by human antithrombin. Journal of Biological Chemistry 250: 8883
• 18 Thompson AR. 1977; Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B Journal of Clinical Investigation 59: 900
• 19 Zimmerman TS, Ratnoff OD, Powell AE. 1971; Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand’s disease. Journal of Clinical Investigation 50: 244